Prevalence of hepatitis B in Pointe-Noire is 23%. The objective of this study was to evaluate the level of therapeutic management of patients with hepatitis B in Pointe-Noire. Methods: A retrospective, cross-sectional, descriptive and analytical study. Results: 302 patients included: 217 (72%) men and 85 (28%) women of median age 40 years. The viral load was measured in 140 (46%) patients and in 162 (54%), the viral load was not measured. Their distribution according to the viremia was as follows: 0 -1 log = 1 (0.7%) patients; 1.5 to 2 log = 23 (16%) patients; 2.5 to 3 log = 49 (35%) patients; >3log = 55 (39%) patients. Of the 302 patients included, 36 (11%) patients were treated with antivirals and 253 (83%) patients were not. Conclusion: The number of patients treated for chronic viral hepatitis B was low. Our results show interest for improved preventive and curative management of hepatitis B in Congo in order to reduce the existing high prevalence.
Introduction
[4] [5] . In Sub-Saharan Africa, several studies estimated between 10% and 15% a sero-prevalence of hepatitis B virus surface antigen (HBsAg) [6] [7] [8] [9] [10].
In Congo-Brazzaville, this sero-prevalence was estimated between 9% and 11.6% [11] [12] [13] . However, antiviral treatment of chronic viral hepatitis B in Congo-Brazzaville has not yet become a standard practice among hepatogastroenterologists and infectiologists due to the unavailability of drugs, high cost and poor status of patients. However, access to treatment for patients has not been evaluated.
In this context, we conducted this hospital study in Pointe Noire designed to describe the healthcare path of viral hepatitis patients in Congo, identify the shortcomings in the care offered to hepatitis B patients and difficulties that patients encounter for access to treatment, in order to improve the supply of care in Congo.
Material and Methods

Study Design and Period
We performed retrospective, monocentric, cross-sectional, descriptive and analytical study in 2016, which included patients monitored in the hepatogastroen- 
Criteria for Inclusion
Were Included in study: 
Criteria for Non-Inclusion
Only, patients with acute viral hepatitis B were not included.
Study Variables
Study variables included socio-demographic characteristics, eating behaviour and clinical data, source of health care funding. Data collection was conducted by a single investigator using a medical record review grid pre-tested.
Variables retained for the analyses were following: 1) Sociodemographic characteristics: age (year) and sex.
2) Eating behavior: consumption of alcohol, tobacco or drugs.
3) Clinical data: Co-morbidities (viral co-infections and chronic non communi- 
Sampling
We performed an exhaustive study including medical records that met the eligibility criteria. Thus, the size of our sample was not known in advance.
Statistical Analysis
Descriptive statistics were used to determine study population characteristics.
Patients were classified by sex. Group comparisons used Pearson Chi-2 or Fisher's exact tests. The p-value was 0.05 for statistical significance. Statistical analyses were performed using SPSS v15 (SPSS, Inc., Chicago, Illinois, USA) software.
Ethical Considerations and Conflicts of Interest
The study protocol was approved by the departmental committee of ethics in biomedical research. The authors have no conflicts of interest.
Results
A total of 302 patients from our active file of viral hepatitis B were included; 217 Details about probable mode of contamination are shown in Details of hepatitis B deoxyribonucleic acid (DNA) level are shown in Table 2 .
Among patients with chronic hepatitis B, only 16% patients had accessed to antiviral treatment.The treatment received by patients were: Pegylated interferon alone in 6 (2%) patients, Tenofovir alone in 35 (11.5%) patients and Tenofovir + other antivirals 5 (1.5%) patients. Financing of care was provided by: health insurance for 11 (3.6%) patients, employer for 4 (1.3%) patients, personal funds for 11 (3.6%) patients, parents for 2 (0.6%) patients. Source of funding was not specified for 21 (6.9%) patients. 
Discussion
Chronic viral hepatitis B remains a major public health problem, particularly in That can explain a high prevalence and the low rate of access to treatment. Indeed, only 46% of our patients had accessed to confirmation test in CERBA laboratory (Paris) due to the non-availability of technical equipment in Congo.
In our study, only 16% of patients have received antiviral treatment for hepatitis . Despite our results, some study limitations need to be recognized. Design of our study (retrospective) limits the choice of variables that were analyzed in our study. Indeed, that restricts the in-depth analysis of factors that influencing non access to treatment among our patients.
Prospective cohort study would have been better adapted to assess our patients' recovery time and especially the factors that lead to patients not having access to treatment [14] .
Conclusion
The number of patients treated for chronic viral hepatitis B in Pointe-Noire was low. Our results show interest for improved preventive and curative management of hepatitis B in Congo in order to reduce the existing high prevalence.
